Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase

INTRODUCTION: The incidence of grade 3–4 anemia was reported to be 3% with imatinib therapy for newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP). However, there are few data regarding the causes and the development of anemia after long-term treatment. This study aimed to eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Moura, Muriel Silva, Benevides, Thais Celi Lopes, Delamain, Marcia Torresan, Duarte, Gislaine Oliveira, Percout, Priscila Oliveira, Dias, Maria Almeida, Zulli, Roberto, Souza, Carmino Antonio de, Lorand-Metze, Irene, Pagnano, Katia Borgia Barbosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978532/
https://www.ncbi.nlm.nih.gov/pubmed/31395459
http://dx.doi.org/10.1016/j.htct.2019.03.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978532/
https://www.ncbi.nlm.nih.gov/pubmed/31395459
http://dx.doi.org/10.1016/j.htct.2019.03.006

Ejemplares similares